| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
*
Clinical Research Division, Fred Hutchinson Cancer Research Center, and Departments of Medicine and Immunology, University of Washington, Seattle, WA 98109;
The Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305; and
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305
Immunogenic peptides of human tumor Ag have been used to generate antigen-specific CTL. However, the vast majority of these peptide-specific CTL clones are of low avidity and are peptide, but not tumor, reactive. Peptide-MHC tetramers have been shown to bind specific TCRs with sufficient affinity to be useful reagents for flow cytometry. In this paper we demonstrate that peptide-MHC tetramers can also be used to selectively identify high avidity tumor-reactive CTL and enrich, from a heterogeneous population, the subpopulation of peptide-reactive T cells that can lyse tumor targets. The melanoma proteins, MART-1 and gp100, were used to induce potentially tumor-reactive T cells, and the intensity of T cell staining by TCR binding of specific peptide-MHC tetramers was assessed. A range of fluorescence intensity was detected, and the magnitude of tetramer binding was correlated with T cell avidity. The population of peptide-reactive T cells was phenotypically similar with regard to expression of TCR and adhesion molecules, suggesting that this differential avidity for tumor cells reflected differential affinity of the TCR for its peptide-MHC ligand. Sorting, cloning, and expansion of tetramerhigh CTL from a heterogeneous population of peptide-stimulated PBMCs enabled rapid selection of high avidity tumor-reactive CTL clones, which retained their functional and tetramerhigh phenotype on re-expansion. These results demonstrate that the avidity of a T cell for its tumor target is due to the specific affinity of the TCR for its peptide-MHC ligand, that this interaction can be described using peptide-MHC tetramers and used to isolate high avidity tumor-reactive CTL.
This article has been cited by other articles:
|
|
 |
|
  M. J. Turner, E. R. Jellison, E. G. Lingenheld, L. Puddington, and L. Lefrancois Avidity maturation of memory CD8 T cells is limited by self-antigen expression J. Exp. Med., August 4, 2008; 205(8): 1859 - 1868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Andrews, C. D. Pack, and A. E. Lukacher Generation of Antiviral Major Histocompatibility Complex Class I-Restricted T Cells in the Absence of CD8 Coreceptors J. Virol., May 15, 2008; 82(10): 4697 - 4705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Kroger, S. Amoah, and M. A. Alexander-Miller Cutting Edge: Dendritic Cells Prime a High Avidity CTL Response Independent of the Level of Presented Antigen J. Immunol., May 1, 2008; 180(9): 5784 - 5788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Belyakov, S. Kozlowski, M. Mage, J. D. Ahlers, L. F. Boyd, D. H. Margulies, and J. A. Berzofsky Role of {alpha}3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs Int. Immunol., December 1, 2007; 19(12): 1413 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yang, E. M. Wall, K. Milne, P. Theiss, P. Watson, and B. H. Nelson CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15 Dependent Mechanism Clin. Cancer Res., December 1, 2007; 13(23): 7172 - 7180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Laugel, H. A. van den Berg, E. Gostick, D. K. Cole, L. Wooldridge, J. Boulter, A. Milicic, D. A. Price, and A. K. Sewell Different T Cell Receptor Affinity Thresholds and CD8 Coreceptor Dependence Govern Cytotoxic T Lymphocyte Activation and Tetramer Binding Properties J. Biol. Chem., August 17, 2007; 282(33): 23799 - 23810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Marrack Conference Summary Proceedings of the ATS, August 15, 2007; 4(5): 469 - 471. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Kroger and M. A. Alexander-Miller Cutting Edge: CD8+ T Cell Clones Possess the Potential to Differentiate into both High- and Low-Avidity Effector Cells J. Immunol., July 15, 2007; 179(2): 748 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Cush, K. M. Anderson, D. H. Ravneberg, J. L. Weslow-Schmidt, and E. Flano Memory Generation and Maintenance of CD8+ T Cell Function during Viral Persistence J. Immunol., July 1, 2007; 179(1): 141 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ranasinghe, S. J. Turner, C. McArthur, D. B. Sutherland, J.-H. Kim, P. C. Doherty, and I. A. Ramshaw Mucosal HIV-1 Pox Virus Prime-Boost Immunization Induces High-Avidity CD8+ T Cells with Regime-Dependent Cytokine/Granzyme B Profiles J. Immunol., February 15, 2007; 178(4): 2370 - 2379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Lyons, T. Moore, N. Brasic, M. Li, J. J. Roszkowski, and M. I. Nishimura Influence of Human CD8 on Antigen Recognition by T-Cell Receptor-Transduced Cells Cancer Res., December 1, 2006; 66(23): 11455 - 11461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Archbold, W. A. Macdonald, J. J. Miles, R. M. Brennan, L. Kjer-Nielsen, J. McCluskey, S. R. Burrows, and J. Rossjohn Alloreactivity between Disparate Cognate and Allogeneic pMHC-I Complexes Is the Result of Highly Focused, Peptide-dependent Structural Mimicry J. Biol. Chem., November 10, 2006; 281(45): 34324 - 34332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Brown, C. Blank, J. Kline, A. K. Kacha, and T. F. Gajewski Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection J. Immunol., October 1, 2006; 177(7): 4521 - 4529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Guillaume, P. Baumgaertner, G. S. Angelov, D. Speiser, and I. F. Luescher Fluorescence-Activated Cell Sorting and Cloning of Bona Fide CD8+ CTL with Reversible MHC-Peptide and Antibody Fab' Conjugates J. Immunol., September 15, 2006; 177(6): 3903 - 3912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. McWilliams, S. M. McGurran, S. W. Dow, J. E. Slansky, and R. M. Kedl A Modified Tyrosinase-Related Protein 2 Epitope Generates High-Affinity Tumor-Specific T Cells but Does Not Mediate Therapeutic Efficacy in an Intradermal Tumor Model J. Immunol., July 1, 2006; 177(1): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Neveu, K. Echasserieau, T. Hill, K. Kuus-Reichel, E. Houssaint, M. Bonneville, and X. Saulquin Impact of CD8-MHC class I interaction in detection and sorting efficiencies of antigen-specific T cells using MHC class I/peptide multimers: contribution of pMHC valency Int. Immunol., July 1, 2006; 18(7): 1139 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. M. Boon, G. de Mutsert, R. A. M. Fouchier, A. D. M. E. Osterhaus, and G. F. Rimmelzwaan The Hypervariable Immunodominant NP418-426 Epitope from the Influenza A Virus Nucleoprotein Is Recognized by Cytotoxic T Lymphocytes with High Functional Avidity. J. Virol., June 1, 2006; 80(12): 6024 - 6032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Eguchi, M. Hatano, F. Nishimura, X. Zhu, J. E. Dusak, H. Sato, I. F. Pollack, W. J. Storkus, and H. Okada Identification of Interleukin-13 Receptor {alpha}2 Peptide Analogues Capable of Inducing Improved Antiglioma CTL Responses Cancer Res., June 1, 2006; 66(11): 5883 - 5891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Reits, J. W. Hodge, C. A. Herberts, T. A. Groothuis, M. Chakraborty, E. K.Wansley, K. Camphausen, R. M. Luiten, A. H. de Ru, J. Neijssen, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy J. Exp. Med., May 15, 2006; 203(5): 1259 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Curigliano, G. Spitaleri, E. Pietri, M. Rescigno, F. de Braud, A. Cardillo, E. Munzone, A. Rocca, G. Bonizzi, V. Brichard, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann. Onc., May 1, 2006; 17(5): 750 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. van den Broeke, C. D. Pendleton, C. Mackall, L. J. Helman, and J. A. Berzofsky Identification and Epitope Enhancement of a PAX-FKHR Fusion Protein Breakpoint Epitope in Alveolar Rhabdomyosarcoma Cells Created by a Tumorigenic Chromosomal Translocation Inducing CTL Capable of Lysing Human Tumors Cancer Res., February 1, 2006; 66(3): 1818 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yang, J. W. Hodge, D. W. Grosenbach, and J. Schlom Vaccines with Enhanced Costimulation Maintain High Avidity Memory CTL J. Immunol., September 15, 2005; 175(6): 3715 - 3723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, M. Bleakley, and C. Yee IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response J. Immunol., August 15, 2005; 175(4): 2261 - 2269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kedzierska, N. L. La Gruta, M. P. Davenport, S. J. Turner, and P. C. Doherty Contribution of T cell receptor affinity to overall avidity for virus-specific CD8+ T cell responses PNAS, August 9, 2005; 102(32): 11432 - 11437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yang, K.-Y. Tsang, and J. Schlom Induction of Higher-Avidity Human CTLs by Vector-Mediated Enhanced Costimulation of Antigen-Presenting Cells Clin. Cancer Res., August 1, 2005; 11(15): 5603 - 5615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gannage, M. Abel, A.-S. Michallet, S. Delluc, M. Lambert, S. Giraudier, R. Kratzer, G. Niedermann, L. Saveanu, F. Guilhot, et al. Ex Vivo Characterization of Multiepitopic Tumor-Specific CD8 T Cells in Patients with Chronic Myeloid Leukemia: Implications for Vaccine Development and Adoptive Cellular Immunotherapy J. Immunol., June 15, 2005; 174(12): 8210 - 8218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Ercolini, B. H. Ladle, E. A. Manning, L. W. Pfannenstiel, T. D. Armstrong, J.-P. H. Machiels, J. G. Bieler, L. A. Emens, R. T. Reilly, and E. M. Jaffee Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response J. Exp. Med., May 16, 2005; 201(10): 1591 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Hodge, M. Chakraborty, C. Kudo-Saito, C. T. Garnett, and J. Schlom Multiple Costimulatory Modalities Enhance CTL Avidity J. Immunol., May 15, 2005; 174(10): 5994 - 6004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kawano, C. L. Efferson, G. E. Peoples, D. Carter, N. Tsuda, J. L. Murray, and C. G. Ioannides Sensitivity of Undifferentiated, High-TCR Density CD8+ Cells to Methylene Groups Appended to Tumor Antigen Determines Their Differentiation or Death Cancer Res., April 1, 2005; 65(7): 2930 - 2937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Lyman, C. T. Nugent, K. L. Marquardt, J. A. Biggs, E. G. Pamer, and L. A. Sherman The Fate of Low Affinity Tumor-Specific CD8+ T Cells in Tumor-Bearing Mice J. Immunol., March 1, 2005; 174(5): 2563 - 2572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oh, L. P. Perera, D. S. Burke, T. A. Waldmann, and J. A. Berzofsky IL-15/IL-15R{alpha}-mediated avidity maturation of memory CD8+ T cells PNAS, October 19, 2004; 101(42): 15154 - 15159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Leggatt, S. Narayan, G. J. P. Fernando, and I. H. Frazer Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes J. Leukoc. Biol., October 1, 2004; 76(4): 787 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Reijonen, R. Mallone, A.-K. Heninger, E. M. Laughlin, S. A. Kochik, B. Falk, W. W. Kwok, C. Greenbaum, and G. T. Nepom GAD65-Specific CD4+ T-Cells with High Antigen Avidity Are Prevalent in Peripheral Blood of Patients With Type 1 Diabetes Diabetes, August 1, 2004; 53(8): 1987 - 1994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Korangy, L. A. Ormandy, J. S. Bleck, J. Klempnauer, L. Wilkens, M. P. Manns, and T. F. Greten Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma Clin. Cancer Res., July 1, 2004; 10(13): 4332 - 4341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Paczesny, J. Banchereau, K. M. Wittkowski, G. Saracino, J. Fay, and A. K. Palucka Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells J. Exp. Med., June 7, 2004; 199(11): 1503 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Maus, B. Kovacs, W. W. Kwok, G. T. Nepom, K. Schlienger, J. L. Riley, D. Allman, T. H. Finkel, and C. H. June Extensive Replicative Capacity of Human Central Memory T Cells J. Immunol., June 1, 2004; 172(11): 6675 - 6683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yang and F. G. Haluska Treatment of Melanoma with 5-Fluorouracil or Dacarbazine In Vitro Sensitizes Cells to Antigen-Specific CTL Lysis through Perforin/Granzyme- and Fas-Mediated Pathways J. Immunol., April 1, 2004; 172(7): 4599 - 4608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Movassagh, A. Spatz, J. Davoust, S. Lebecque, P. Romero, M. Pittet, D. Rimoldi, D. Lienard, O. Gugerli, L. Ferradini, et al. Selective Accumulation of Mature DC-Lamp+ Dendritic Cells in Tumor Sites Is Associated with Efficient T-Cell-Mediated Antitumor Response and Control of Metastatic Dissemination in Melanoma Cancer Res., March 15, 2004; 64(6): 2192 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Mapara and M. Sykes Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Schell In Vivo Expansion of the Residual Tumor Antigen-Specific CD8+ T Lymphocytes That Survive Negative Selection in Simian Virus 40 T-Antigen-Transgenic Mice J. Virol., February 15, 2004; 78(4): 1751 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ramirez, Y. Ghani, and H. Stauss Incomplete tolerance to the tumour-associated antigen MDM2 Int. Immunol., February 1, 2004; 16(2): 327 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, and R. W. Dutton Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses J. Immunol., February 1, 2004; 172(3): 1380 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, J. C. Hylind, and R. W. Dutton Effector Cell-Derived Lymphotoxin {alpha} and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases Cancer Res., January 1, 2004; 64(1): 406 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Butterfield, A. Ribas, W. S. Meng, V. B. Dissette, S. Amarnani, H. T. Vu, E. Seja, K. Todd, J. A. Glaspy, W. H. McBride, et al. T-Cell Responses to HLA-A*0201 Immunodominant Peptides Derived from {alpha}-Fetoprotein in Patients with Hepatocellular Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5902 - 5908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nikiforow, K. Bottomly, G. Miller, and C. Munz Cytolytic CD4+-T-Cell Clones Reactive to EBNA1 Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation J. Virol., November 15, 2003; 77(22): 12088 - 12104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Walter, L. Herrgen, O. Schoor, G. Jung, D. Wernet, H.-J. Buhring, H.-G. Rammensee, and S. Stevanovic Cutting Edge: Predetermined Avidity of Human CD8 T Cells Expanded on Calibrated MHC/Anti-CD28-Coated Microspheres J. Immunol., November 15, 2003; 171(10): 4974 - 4978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M.-L. Choi, J.-L. Chen, L. Wooldridge, M. Salio, A. Lissina, N. Lissin, I. F. Hermans, J. D. Silk, F. Mirza, M. J. Palmowski, et al. High Avidity Antigen-Specific CTL Identified by CD8-Independent Tetramer Staining J. Immunol., November 15, 2003; 171(10): 5116 - 5123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Maecker, D. H. Sherr, R. H. Vonderheide, M. S. von Bergwelt-Baildon, N. Hirano, K. S. Anderson, Z. Xia, M. O. Butler, K. W. Wucherpfennig, C. O'Hara, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells Blood, November 1, 2003; 102(9): 3287 - 3294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cao, J. McNevin, U. Malhotra, and M. J. McElrath Evolution of CD8+ T Cell Immunity and Viral Escape Following Acute HIV-1 Infection J. Immunol., October 1, 2003; 171(7): 3837 - 3846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Maris, J. D. Miller, J. D. Altman, and J. Jacob A Transgenic Mouse Model Genetically Tags All Activated CD8 T Cells J. Immunol., September 1, 2003; 171(5): 2393 - 2401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Pittet, V. Rubio-Godoy, G. Bioley, P. Guillaume, P. Batard, D. Speiser, I. Luescher, J.-C. Cerottini, P. Romero, and A. Zippelius {alpha}3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T Cells J. Immunol., August 15, 2003; 171(4): 1844 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Ko, K. Kawano, J. L. Murray, M. L. Disis, C. L. Efferson, H. M. Kuerer, G. E. Peoples, and C. G. Ioannides Clinical Studies of Vaccines Targeting Breast Cancer Clin. Cancer Res., August 1, 2003; 9(9): 3222 - 3234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oh, J. W. Hodge, J. D. Ahlers, D. S. Burke, J. Schlom, and J. A. Berzofsky Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC J. Immunol., March 1, 2003; 170(5): 2523 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kuzushima, N. Hayashi, A. Kudoh, Y. Akatsuka, K. Tsujimura, Y. Morishima, and T. Tsurumi Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells Blood, February 15, 2003; 101(4): 1460 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Slifka, J. N. Blattman, D. J. D. Sourdive, F. Liu, D. L. Huffman, T. Wolfe, A. Hughes, M. B. A. Oldstone, R. Ahmed, and M. G. von Herrath Preferential Escape of Subdominant CD8+ T Cells During Negative Selection Results in an Altered Antiviral T Cell Hierarchy J. Immunol., February 1, 2003; 170(3): 1231 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. D. Davis, M. Jefford, P. Parente, and J. Cebon Rational approaches to human cancer immunotherapy J. Leukoc. Biol., January 1, 2003; 73(1): 3 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yee, J. A. Thompson, D. Byrd, S. R. Riddell, P. Roche, E. Celis, and P. D. Greenberg Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells PNAS, December 10, 2002; 99(25): 16168 - 16173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Cawthon and M. A. Alexander-Miller Optimal Colocalization of TCR and CD8 as a Novel Mechanism for the Control of Functional Avidity J. Immunol., October 1, 2002; 169(7): 3492 - 3498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hernandez, F. Garcia-Pons, Y. C. Lone, H. Firat, J. D. Schmidt, P. Langlade-Demoyen, and M. Zanetti Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells PNAS, September 17, 2002; 99(19): 12275 - 12280. [Abstract] [Full Text] [PDF]
|
|
